Praxis Biologics Inc

Basic Information

30 Corporate Woods
Rochester, NY, 14623

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. ORAL MALARIA VACCINE DEVELOPMENT IN A PLASMODIUM BERGHEI MODEL

    Amount: $500,000.00

    PEPTIDE CARRIER AND RECOMBINANT DNA-PRODUCED PLASMODIUM FALCIPARUM SPOROZOITE SUBUNIT VACCINES HAVE BEEN TESTED IN CLINICAL TRIALS. THESE VACCINES HAVE BEEN DESIGNED TO INDUCE HIGH-TITER PROTECTIVE AN ...

    SBIR Phase II 1989 Department of Health and Human Services
  2. FUSIONS OF AN HAEMOPHILUS PAL AS VACCINE CANDIDATES.

    Amount: $500,000.00

    HAEMOPHILUS INFLUENZAE TYPE B (HIB) POLYSACCHARIDE AND POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES HAVE BEEN PROVEN EFFECTIVE AGAINST HIB DISEASE. HOWEVER, CAPSULAR ANTIGEN ISOF NO VALUE AGAINST NON-TYP ...

    SBIR Phase II 1989 Department of Health and Human Services
  3. RECOMBINANT FLAGELLIN VACCINES

    Amount: $46,876.00

    PRAXIS BIOLOGICS, INC., WILL CONDUCT EXPERIMENTS TO ASSESS THE POTENTIAL OF USING BACTERIAL FLAGELLA AS CARRIERS OF FOREIGN ANTIGENIC DETERMINANTS. RECOMBINANT DNA TECHNIQUES WILL BE USED TO CONSTRUCT ...

    SBIR Phase I 1989 Department of Health and Human Services
  4. SYNTHETIC CLYCO-CONJUGATE VACCINE AGAINST MENINGOCOCCI

    Amount: $50,000.00

    THE OBJECTIVE OF PHASE I IS TO PREPARE SYNTHETIC GLYCO-CONJUGATE VACCINES AGAINST MENINGOCOCCAL DISEASES CAUSED BY NEISSERIA MENINGOCOCCI SEROGROUPS A AND C. N. MENINGITIDIS IS A LEADING CAUSE OF BACT ...

    SBIR Phase I 1989 Department of Health and Human Services
  5. RECOMBINANT ROTAVIRUS PROTEINS FOR SUBUNIT VACCINE

    Amount: $43,136.00

    THE OBJECTIVE OF PHASE I IS TO PRODUCE A ROTAVIRUS ASSEMBLED-SUBUNIT VACCINE USING RECOMBINANT DNA TECHNOLOGY. SPECIFICALLY, BACULOVIRUS-EXPRESSED ROTAVIRUS PROTEINS VP6 AND VP7 WILL BE PURIFIED AND A ...

    SBIR Phase I 1989 Department of Health and Human Services
  6. RECOMBINANT RSV F GENE PRODUCTS AS VACCINE CANDIDATES

    Amount: $50,000.00

    VACCINATION IS THE MOST COST-EFFECTIVE MEANS OF PREVENTING RESPIRATORY SYNCYTIAL VIRUS (RSV) DISEASE. A FEASIBLE APPROACH TO A SAFE RSV VACCINE IS TO MAKE A SUBUNIT OF THE VIRUS, AND THE BEST CANDIDAT ...

    SBIR Phase I 1988 Department of Health and Human Services
  7. PURA COMPLEMENTATION FOR PLASMID SELECTION & MAINTENANCE

    Amount: $50,000.00

    LIVE ATTENUATED SALMONELLA STRAINS ARE BEING INVESTIGATED ASVECTORS FOR THE DELIVERY OF FOREIGN ANTIGENS TO STIMULATE A PROTECTIVE IMMUNE RESPONSE AGAINST VARIOUS BACTERIAL, VIRAL,AND PROTOZOAN DISEAS ...

    SBIR Phase I 1988 Department of Health and Human Services
  8. AN ORAL VACCINE AGAINST ENTEROTOXIGENIC E. COLI

    Amount: $50,000.00

    DIARRHEA IS A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN DEVELOPING COUNTRIES, ESPECIALLY IN INFANTS AND YOUNG CHILDREN. ENTEROTOXIGENIC E. COLI (ETEC) CAUSE A SIGNIFICANT PROPORTION OF THIS DISEASE, A ...

    SBIR Phase I 1988 Department of Health and Human Services
  9. MUTANT NONTOXIC FORMS OF PERTUSS TOXIN FOR VACCINES

    Amount: $50,000.00

    PERTUSSIS TOXIN (PT) IS AN IMPORTANT IMMUNOGEN FOR DEVELOPMENT OF IMMUNITY TO PERTUSSIS, AND CHEMICALLY INACTIVATED PT IS A MAJOR COMPONENT OF ACELLULAR PERTUSSIS VACCINES BEING TESTED IN THE CLINIC. ...

    SBIR Phase I 1988 Department of Health and Human Services
  10. SYNTHETIC PEPTIDES AS CARRIERS FOR CONJUGATE VACCINES.

    Amount: $50,000.00

    THE LONG TERM OBJECTIVE OF THIS RESEARCH IS TO GENERATE BACTERIAL CAPSULAR POLYSACCHARIDE-PEPTIDE CONJUGATE VACCINESTHAT WILL PROTECT INFANTS, WHO UNLIKE OLDER CHILDREN AND ADULTS, CAN NOT PRODUCE ANT ...

    SBIR Phase I 1988 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government